Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SKAN Group AG ( (CH:SKAN) ) has provided an announcement.
In the first half of 2025, SKAN Group AG experienced a significant increase in order intake by 20.2% to CHF 213 million and achieved a record order backlog of CHF 386.4 million. Despite this, net sales decreased due to project delays, particularly in vaccine lines, leading to a slightly positive EBITDA and a negative net result. The company is advancing strategic initiatives for integrated process systems and standardization, and the recent acquisition of Metronik enhances its offerings across the pharmaceutical value chain. SKAN remains confident in achieving its full-year guidance, supported by a strong order pipeline and pre-productions of standard isolators.
The most recent analyst rating on (CH:SKAN) stock is a Buy with a CHF92.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.
More about SKAN Group AG
SKAN Group AG is a leading provider of high-quality isolator systems for aseptic production processes in the pharmaceutical and biotech industries. The company specializes in complex aseptic-toxic large-scale systems, particularly for modern oncology drugs such as Antibody Drug Conjugates (ADC). SKAN is known for its high-quality technology and process know-how, with a strong market presence in various regions.
Average Trading Volume: 17,061
Technical Sentiment Signal: Sell
Current Market Cap: CHF1.46B
See more data about SKAN stock on TipRanks’ Stock Analysis page.